Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CimetrA for Moderate COVID-19
NCT05037162Phase 2Completed
- Sponsor
- MGC Pharmaceuticals
- Start
- Oct 2022
- Primary completion
- Jan 2023
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of CimetrA in coronavirus disease 2019 (COVID-19), sponsored by MGC Pharmaceuticals. Started Oct 2022; status: completed.
02
Drugs
CimetrA
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05037162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05037162.